Stock A208340 PHARMABCINE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases PharmAbcine Inc.

Equities

A208340

KR7208340000

End-of-day quote Korea S.E.
Other stock markets
 04:30:00 19/01/2024 am IST 		5-day change 1st Jan Change
2,915 KRW -8.91% Intraday chart for PharmAbcine Inc. -.--% -22.27%
24/01 PharmAbcine Inc. Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA®? (Pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors CI
2023 PharmAbcine Inc. announced that it has received KRW 5.000000492 billion in funding CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology Annual Meeting 2024
AQ
PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA in Patients with Advanced or Metastatic Solid Tumors
AQ
PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration following Dose Level 1 Safety Data
AQ
PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcase 2023 during JPM Week
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A208340 Stock
  4. News PharmAbcine Inc.
  5. Press Releases